PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has four Cxbladder products in the market: Detect, Triage, Monitor and Resolve. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262
Share price performance
All stock prices and news delayed 20 minutes
02:03 August 15th 2018 NZST
0.31 1.6%
0.30 Buy
0.31 Sell
Last 0.31
Open 0.31
High 0.31
Low 0.31
Volume 74,783
Turnover $23,026
Most recent trades All trades for the day
| Time | Price | Volume | Value |
|---|---|---|---|
| 17:00 | 0.31 | 3,000 | $930.00 |
| 17:00 | 0.31 | 2,001 | $620.31 |
| 17:00 | 0.31 | 29,999 | $9,299.69 |
| 16:22 | 0.31 | 2,499 | $774.69 |
| 15:10 | 0.31 | 11,333 | $3,456.57 |
Latest Pacific Edge Limited research
Today's trades
| Trade Number | Time | Price | Volume | Value |
|---|---|---|---|---|
| 7 | 17:00 | 0.31 | 3,000 | $930.00 |
| 6 | 17:00 | 0.31 | 2,001 | $620.31 |
| 5 | 17:00 | 0.31 | 29,999 | $9,299.69 |
| 4 | 16:22 | 0.31 | 2,499 | $774.69 |
| 3 | 15:10 | 0.31 | 11,333 | $3,456.57 |
| 2 | 13:33 | 0.31 | 9,132 | $2,785.26 |
| 1 | 13:31 | 0.31 | 10,815 | $3,298.58 |